Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

181. Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An Update.

Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An Update. The latest guidelines from the American College of Cardiology and American Heart Association, released in fall 2013, provide a long-anticipated update to the recommendations of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). The guidelines incorporate a new risk score (...) for atherosclerotic cardiovascular disease that includes stroke as well as coronary heart disease. After publication, the new pooled cohort equations (PCEs) were evaluated in 15 studies from the United States and Europe, most of which used cohorts that were more contemporary than those used in developing the guidelines. In almost all of these external validation cohorts, the PCEs overestimated the observed risk. This narrative review provides an update of the published reports, an overview of the strengths

Annals of Internal Medicine2016

182. Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism

Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism 27840737 2018 11 13 2059-7908 1 3 2016 BMJ global health BMJ Glob Health Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. e000105 Low and middle income countries (LMICs) bear a huge, disproportionate and growing burden of cardiovascular disease (CVD) which constitutes a threat to development. Efforts to tackle the global burden of CVD must (...) May;125(5):433-9 22482843 Stroke. 2013 Mar;44(3):870-947 23370205 The authors are members of the Global Alliance for Chronic Diseases—COntrol UNique to Cardiovascular diseases In LMICs—(GACD-COUNCIL) initiative. GACD is the first alliance of the world’s biggest public research funding agencies, which currently is funding 15 hypertension and 16 diabetes implementation science projects in LMICs. MO is the pioneer chair of the H3Africa CVD research consortium, the largest in Africa with projected

BMJ global health2016 Full Text: Link to full Text with Trip Pro

184. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult

2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

CMA Infobase (Canada)2016

185. An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey

An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey 27487404 2018 09 17 2018 11 13 2380-6591 1 7 2016 10 01 JAMA cardiology JAMA Cardiol An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey. 779-786 10.1001/jamacardio.2016.2173 Electrocardiography (ECG) may detect subclinical cardiovascular disease (CVD) in asymptomatic individuals (...) 11085961 Adult Aged Cardiovascular Diseases epidemiology Electrocardiography Female Humans Male Middle Aged Nutrition Surveys Risk Assessment Risk Factors 2016 10 21 6 0 2018 9 18 6 0 2016 8 4 6 0 ppublish 27487404 2540547 10.1001/jamacardio.2016.2173 PMC5881386 NIHMS952144

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

186. Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen

Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen 27626902 2018 08 09 2018 11 13 2380-6591 1 7 2016 10 01 JAMA cardiology JAMA Cardiol Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen. 776-777 10.1001/jamacardio.2016.2662 Manson JoAnn E JE Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Woodruff Teresa K TK Division of Reproductive (...) Menopause. 2006 Mar-Apr;13(2):265-79 16645540 JAMA Cardiol. 2016 Oct 1;1(7):767-776 27627190 Biomarkers Cardiovascular Diseases Estrogen Receptor alpha Estrogen Replacement Therapy Estrogens Humans Menopause Receptors, Estrogen Reproductive Health Risk Factors Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. 2016 10 21 6 0 2018 8 10 6 0 2016 9 15 6 0 ppublish 27626902 2551979 10.1001/jamacardio.2016.2662

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

187. Omega-3 fatty acids and cardiovascular disease: an updated systematic review

Omega-3 fatty acids and cardiovascular disease: an updated systematic review Omega-3 fatty acids and cardiovascular disease: an updated systematic review Omega-3 fatty acids and cardiovascular disease: an updated systematic review Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 223. 2016 Authors' objectives Evaluate the effect of omega−3 fatty acids (n-3 FA) on clinical and selected

Health Technology Assessment (HTA) Database.2016

188. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. BACKGROUND: The optimum blood pressure target in hypertension remains debated, especially in coronary artery disease, given concerns for reduced myocardial perfusion if diastolic blood pressure is too low. We aimed to study the association between achieved blood pressure and cardiovascular outcomes in patients (...) with coronary artery disease and hypertension. METHODS: We analysed data from 22 672 patients with stable coronary artery disease enrolled (from Nov 26, 2009, to June 30, 2010) in the CLARIFY registry (including patients from 45 countries) and treated for hypertension. Systolic and diastolic blood pressures before each event were averaged and categorised into 10 mm Hg increments. The primary outcome was the composite of cardiovascular death, myocardial infarction, or stroke. Hazard ratios (HRs) were

Lancet2016

189. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. IMPORTANCE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently approved for lowering low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) and have potential for broad ASCVD prevention. Their long-term cost-effectiveness and effect (...) on total health care spending are uncertain. OBJECTIVE: To estimate the cost-effectiveness of PCSK9 inhibitors and their potential effect on US health care spending. DESIGN, SETTING, AND PARTICIPANTS: The Cardiovascular Disease Policy Model, a simulation model of US adults aged 35 to 94 years, was used to evaluate cost-effectiveness of PCSK9 inhibitors or ezetimibe in heterozygous FH or ASCVD. The model incorporated 2015 annual PCSK9 inhibitor costs of $14,350 (based on mean wholesale acquisition costs

JAMA2016

190. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518673 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):489. doi: 10.1056/NEJMc1606624. Fruit Consumption and Cardiovascular Disease in China. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27518673 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substance Full Text Sources Medical

NEJM2016

191. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518674 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):487-8. doi: 10.1056/NEJMc1606624#SA1. Fruit Consumption and Cardiovascular Disease in China. 1 . 1 Clinical Nutrition Research Center, Singapore, Singapore mleowsj@massmed.org. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518674 DOI: [Indexed for MEDLINE] Publication types MeSH terms

NEJM2016 Full Text: Link to full Text with Trip Pro

192. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518675 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):488. doi: 10.1056/NEJMc1606624#SA2. Fruit Consumption and Cardiovascular Disease in China. 1 . 1 Tel Aviv University, Tel Aviv, Israel eran.kopel@gmx.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518675 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

193. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518676 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):488. doi: 10.1056/NEJMc1606624#SA3. Fruit Consumption and Cardiovascular Disease in China. 1 , 1 . 1 Soochow University, Suzhou, China qinliqiang@suda.edu.cn. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518676 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

194. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.

Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. OBJECTIVES: To compare the risk associated with systolic blood pressure that meets current recommendations (that is, below 140 mm Hg) with the risk associated with lower levels in patients who have type 2 diabetes and no previous cardiovascular disease. DESIGN: Population based cohort study with nationwide clinical registries, 2006-12. The mean (...) follow-up was 5.0 years. SETTING: 861 Swedish primary care units and hospital outpatient clinics. PARTICIPANTS: 187 106 patients registered in the Swedish national diabetes register who had had type 2 diabetes for at least a year, age 75 or younger, and with no previous cardiovascular or other major disease. MAIN OUTCOME MEASURES: Clinical events were obtained from the hospital discharge and death registers with respect to acute myocardial infarction, stroke, a composite of acute

BMJ2016

196. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern mult

Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern mult 27436865 2016 07 20 2017 03 31 1522-9645 38 8 2017 Feb 21 European heart journal Eur. Heart J. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart (...) Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. 598-608 10.1093/eurheartj/ehw301 To evaluate the 2013 American Heart Association (AHA)-American College of Cardiology (ACC)-Atherosclerotic Cardiovascular Disease (ASCVD) risk score among four different race/ethnic groups and to ascertain which factors are most associated with risk overestimation by the AHA-ACC-ASCVD score. The Multi-Ethnic Study of Atherosclerosis (MESA

EvidenceUpdates2016

197. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA])

Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]) 27445216 2016 08 17 2017 01 25 1879-1913 118 5 2016 Sep 01 The American journal of cardiology Am. J. Cardiol. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study (...) of Atherosclerosis [MESA]). 691-6 10.1016/j.amjcard.2016.06.015 S0002-9149(16)31036-0 The increase in statin eligibility by the new cholesterol guidelines is mostly driven by the Pooled Cohort Equation (PCE) criterion (≥7.5% 10-year PCE). The impact of replacing the PCE with either the modified Framingham Risk Score (FRS) or the Systematic Coronary Risk Evaluation (SCORE) on assessment of atherosclerotic cardiovascular disease (ASCVD) risk assessment and statin eligibility remains unknown. We assessed

EvidenceUpdates2016

198. High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training

High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training 28462120 2018 11 13 2213-4220 5 3 2016 Sep Integrative medicine research Integr Med Res High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training. 212-215 10.1016/j.imr.2016.07.001 Decreases in high-density lipoprotein cholesterol (HDL-C) levels are associated with an increased risk of coronary artery disease (CAD), whereas increased HDL-C levels (...) are related to a decreased risk of CAD and myocardial infarction. Although HDL prevents the oxidation of low-density lipoprotein under normal conditions, it triggers a structural change, inhibiting antiarteriosclerotic and anti-inflammatory functions, under pathological conditions such as oxidative stress, inflammation, and diabetes. HDL can transform into various structures based on the quantitative reduction and deformation of apolipoprotein A1 and is the primary cause of increased levels

Integrative medicine research2016 Full Text: Link to full Text with Trip Pro

199. Androgen Deprivation Therapy–Induced Cardiovascular Disease

Androgen Deprivation Therapy–Induced Cardiovascular Disease 28717732 2017 07 19 2378-9506 2 6 2016 Dec Journal of global oncology J Glob Oncol Androgen Deprivation Therapy-Induced Cardiovascular Disease. 438 10.1200/JGO.2016.006015 Dhanushkodi Manikandan M Cancer Institute (WIA), Chennai, India. eng Journal Article 2016 07 27 United States J Glob Oncol 101674751 2378-9506 J Glob Oncol. 2016 Jul 27;2(6):439 28722032 The following represents disclosure information provided by authors

Journal of global oncology2016 Full Text: Link to full Text with Trip Pro

200. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.

Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. OBJECTIVE: To assess associations between risks of cardiovascular disease, heart failure, and all cause mortality and different diabetes drugs in people with type 2 diabetes, particularly newer agents, including gliptins and thiazolidinediones (glitazones). DESIGN: Open cohort study. SETTING: 1243 general practices contributing data to the QResearch database in England (...) . PARTICIPANTS: 469 688 people with type 2 diabetes aged 25-84 years between 1 April 2007 and 31 January 2015. EXPOSURES: Diabetes drugs (glitazones, gliptins, metformin, sulphonylureas, insulin, other) alone and in combination. MAIN OUTCOME MEASURE: First recorded diagnoses of cardiovascular disease, heart failure, and all cause mortality recorded on the patients' primary care, mortality, or hospital record. Cox proportional hazards models were used to estimate hazard ratios for diabetes treatments

BMJ2016